LMY-920 for Treatment of Relapsed or Refractory Myeloma
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Recruiting · NCT05546723 · Registry updated 2024-10-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| LMY-920 for Treatment of Relapsed or Refractory Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2024-10-18 | NCT05546723 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Case Western Reserve University | 78 |
| Luminary Therapeutics | 6 |
| The Cleveland Clinic | 239 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Hospitals Seidman Cancer Center | Cleveland | United States | 10 |